|
| 38065715 | Lipoprotein(a) levels and carotid intima-media thickness in children: A 20-year follow-up study. | J Clin Lipidol | 2024 |
| 37487514 | Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study. | Lancet Diabetes Endocrinol | 2023 |
| 36307922 | Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition. | European Heart Journal - Cardiovascular Pharmacotherapy | 2023 |
| 37855448 | Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. | | 2023 |
| 37850379 | Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. | | 2023 |
| 37840587 | Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment. | Eur Heart J Open | 2023 |
| 37898443 | The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease. | | 2023 |
| 37277261 | Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. | J Clin Lipidol | 2023 |
| 37398493 | CETP and SGLT2 inhibitor combination therapy improves glycemic control. | | 2023 |
| 36697324 | Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model. | | 2023 |
| 37355760 | The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. | Nat Med | 2023 |
| 37354546 | Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. | | 2023 |
| 34636884 | Combination lipid-lowering therapy as first-line strategy in very high-risk patients. | Eur Heart J | 2022 |
| 36047306 | Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions. | Expert Opinion on Pharmacotherapy | 2022 |
| 35648418 | Macular Degeneration and CETP Inhibition. | JAMA Cardiology | 2022 |
| 35953719 | Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. | Nature Medicine | 2022 |
| 35441656 | The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. | Eur Heart J Cardiovasc Pharmacother | 2022 |
| 35757719 | Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders. | Frontiers in Immunology | 2022 |
| 36345867 | Can we revive CETP-inhibitors for the prevention of cardiovascular disease? | Current Opinion in Lipidology | 2022 |
| 36012684 | Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. | International Journal of Molecular Sciences | 2022 |
| 35379578 | Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study. | Journal of Clinical Lipidology | 2022 |
| 36210291 | Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. | Journal of Clinical Lipidology | 2022 |
| 36075246 | Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. | Lancet Diabetes and Endocrinology,The | 2022 |
| 35361488 | Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic. | Atherosclerosis | 2022 |
| 36443827 | Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). | Cardiovasc Diabetol | 2022 |
| 36252994 | Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. | Open Heart | 2022 |
| 34922870 | Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab. | JACC: Cardiovascular Imaging | 2022 |
| 34915054 | A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. | Journal of Hepatology | 2022 |
| 35232215 | A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. | J Am Heart Assoc | 2022 |
| 34849601 | Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? | Cardiovascular Research | 2022 |
| 35331419 | Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia. | Journal of the American College of Cardiology | 2022 |
| 34696496 | Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents. | Viruses | 2021 |
| 32243492 | Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. | Cardiovasc Res | 2021 |
| 33901739 | A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. | Atherosclerosis | 2021 |
| 33470195 | Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. | American Heart Journal | 2021 |
| 33993205 | Association Between Achieved Ï¿-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. | JAMA Cardiol | 2021 |
| 33668055 | Comment on: Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. | Rheumatology | 2021 |
| 34263698 | Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia. | Expert Review of Molecular Diagnostics | 2021 |
| 33663735 | Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. | J Am Coll Cardiol | 2021 |
| 33766264 | New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. | J Am Coll Cardiol | 2021 |
| 33497862 | LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. | Atherosclerosis | 2021 |
| 33496768 | Update on Lipids and Lipoproteins-Reply. | JAMA - Journal of the American Medical Association | 2021 |
| 33065120 | Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. | Am Heart J | 2021 |
| 34374706 | Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]. | Am J Prev Cardiol | 2021 |
| 32717042 | Lipids and Lipoproteins in 2020. | JAMA - Journal of the American Medical Association | 2020 |
| 32187462 | Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. | N Engl J Med | 2020 |
| 31630870 | Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. | Mayo Clin Proc | 2020 |
| 32439006 | Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans. | Journal of the American College of Cardiology | 2020 |
| 34327467 | C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. | Am J Prev Cardiol | 2020 |
| 32766688 | Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. | Cardiovascular Research | 2020 |